LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

LLY

1,010.74

+3.11%↑

JNJ

229.56

+1.07%↑

ABBV

214.58

+2.77%↑

UNH

393.5

+1.7%↑

AZN

185.65

+1.27%↑

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

BrancheGesundheitswesen

21.45 -0.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.45

Max

21.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -21M
Verkäufe	14M 54M
Gewinnspanne	-39.611
Angestellte	178
EBITDA	-3.8M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-3.62% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1B 2.2B
Vorheriger Eröffnungskurs	21.68
Vorheriger Schlusskurs	21.45

Nachrichtenstimmung

By Acuity

50%

157 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Mai 2026, 23:10 UTC

Heiße Aktien

Stocks to Watch: Agilysys, XP

18. Mai 2026, 18:44 UTC

Wichtige Markttreiber

Claritev Shares Recover After Comments About DOJ

18. Mai 2026, 23:55 UTC

Ergebnisse

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. Mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. Mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. Mai 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. Mai 2026, 22:25 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. Mai 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Mai 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

18. Mai 2026, 20:25 UTC

Ergebnisse

Correct: XP 1Q Total Client Assets BRL1.53T

18. Mai 2026, 20:23 UTC

Ergebnisse

XP 1Q Total Client Assets BRL1.53B

18. Mai 2026, 20:19 UTC

Ergebnisse

XP 1Q Adj EPS BRL2.49 >XP

18. Mai 2026, 20:19 UTC

Ergebnisse

XP 1Q Rev BRL4.73B >XP

18. Mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. Mai 2026, 19:00 UTC

Ergebnisse

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. Mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. Mai 2026, 18:17 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. Mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. Mai 2026, 16:57 UTC

Akquisitionen, Fusionen, Übernahmen

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. Mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. Mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. Mai 2026, 16:54 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci Doesn't Set Out Financial Details of Deal

18. Mai 2026, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. Mai 2026, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. Mai 2026, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. Mai 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci Buys Canada's Modern Group of Companies

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

-3.62% Nachteil

12-Monats-Prognose

Durchschnitt 20.75 USD -3.62%

Hoch 21.5 USD

Tief 17 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

157 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.